Moody's Ratings (Moody's) says that Danaher Corporation's ("Danaher"; A2 stable) announcement on 17 February that it entered into a definitive agreement to acquire Masimo Corporation ("Masimo") for approximately $9.9 billion in total enterprise value will bolster its diagnostics segment while also m...
Two Directors at Thermo Fisher Scientific Inc sold 413 shares at between 0.000USD and 541.200USD. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Strategic decisions will come into the focus of Kai Beckmann after he takes over the CEO role, in our view. We identify the Healthcare segment as being in the focus on improving its growth profile through divestments and acquisitions. Divesting the MS business would boost the segmental sales CAGR to 3.1% from 1.0%. We see more opportunity on the upside and reiterate our Outperform rating with a new target price of € 151.
Weiter auf Erholungskurs: Q4/25-Konzernumsatz stieg mit nom. 2,3 % YoY auf € 927 Mio. das adj. EBITDA (wg. Volumen+ Mix> neg. FX-Effekt) auf € 278 Mio. (+7,3 %; Marge 29,9 %; Vj.: 28,5 %) gegenüber erstmals gestiegenemVorjahreswert. Die rollierende Book-to-Bill-Ratio (temporärer, ergänzender KPI) liege für Q4/25 „deutlich über 100 %“; die Orderqualität sei gut. Das ist die Grundlage für die am 03.02.26 erstveröffentlichte (und recht breit gefasste) Guidance FY 26. Das Wachstum in der dominie...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.